New York, December 22, 2023 - Gilead Sciences (Nasdaq: GILD) has purchased 15 million shares of immunotherapeutics company, HOOKIPA Pharma’s (Nasdaq: HOOK), common stock for approximately $21.25 million, at a price of $1.4167 per share. Under the agreement, HOOKIPA is responsible for advancing its HIV program through the completion of a Phase 1b clinical trial. The company’s shares rose 52.65% on Thursday and 80.51% premarket on Friday. https://prismmarketview.com/companies/hookipa-pharma-inc/...